Neuropace Inc (NPCE NASDAQ) stock market data APIs
$9.5904
0.67(7%)
as of July 11, 2025
Try our APIs with
free plan!
Neuropace Inc Financial Data Overview
Price chart is built with
Anychart
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet and patient data management system; and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Prev. Close
9.5904
Open
10.258
High
10.2336
Low
9.519
52 wk Range
5.45-18.975
Market Cap
312 M
Shares Outstanding
32 799 K
Revenue
84 306 K
EPS
-0.21
Beta
2.042
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Neuropace Inc data using free add-ons & libraries
Get Neuropace Inc Fundamental Data
Neuropace Inc Fundamental data includes:
- Net Revenue: 84 306 K
- EBITDA: -19 062 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-06-06
- EPS/Forecast: -0.32
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Neuropace Inc News
New
NeuroPace's SWOT analysis: innovative epilepsy treatment stock faces growth hurdles
NeuroPace, Inc. (NASDAQ:NPCE), a medical device company with a market capitalization of $341 million specializing in responsive neurostimulation for epilepsy treatment, has been making waves in the he...
NeuroPace stock rating reiterated at Overweight by Cantor Fitzgerald
Investing.com - Cantor Fitzgerald maintained its Overweight rating and $16.00 price target on NeuroPace Inc (NASDAQ:NPCE) on Monday following the company’s announcement of a new chief financial offi...
NeuroPace appoints Patrick Williams as CFO
* NeuroPace (NASDAQ:NPCE [https://seekingalpha.com/symbol/NPCE]) has announced the appointment of Mr. Patrick F. Williams as CFO, effective June 20, 2025 [https://seekingalpha.com/pr/20146644-neurop...
NeuroPace Announces Strategic CFO Transition
Appoints Patrick F. Williams as Chief Financial Officer Williams Brings a Track Record of Leading Medical Device Public Companies as CFO Rebecca Kuhn Departing Company and Will Remain in Advisory Ro...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
